Clinical Trial Update: EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) [Phase 2]

View source ↗

Summary

Phase 2 trial EN3835 for edematous fibrosclerotic panniculopathy (cellulite) completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cellulite
• Edematous Fibrosclerotic Panniculopathy

Drugs mentioned

• EN3835

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Status: COMPLETED | Results posted: 2017-11-06